GWS
AKBA icon

Glassman Wealth Services’s Akebia Therapeutics AKBA Stock Holding History

Glassman Wealth Services’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-30
Closed – – 1044
2019
Q1 		$0 Buy
+30
New +$206 ﹤0.01% 1013

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glassman Wealth Services's AKBA Position: Q2 2019 in Review

Glassman Wealth Services sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 30 shares.

Glassman Wealth Services first reported a position in AKBA in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

  • Glassman Wealth Services reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Glassman Wealth Services sold 30 Akebia Therapeutics shares in Q2 2019.
  • Glassman Wealth Services first reported a position in Akebia Therapeutics in Q1 2019 and held it in 1 quarter.
  • Glassman Wealth Services's Akebia Therapeutics position peaked at $0 in Q1 2019.
  • 151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Glassman Wealth Services's 13F filing for Q2 2019, filed 8 Aug 2019.